sonedenoson
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00312364)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Adenosine A2a receptorAGONIST
ADORA2A agonist
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(OCCc2ccc(Cl)cc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O- Mol. weight
- 421.84 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1950553 ↗
Also known as
- 2-(2-(4-chlorophenyl)ethoxy)adenosine
- mre0094
- mre0094
- mre0094
- mre-0094
- mre-0094
- sonedenoson
- sonedenoson
- sonedenoson
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00318214 | Phase 2 | Jun 1, 2006 | Pfizer |
| NCT00312364 | Phase 2 | Dec 1, 2005 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2005 |
1 organizations
Page 1 / 1